Leading The Way In Pediatric Endo-Cannabinoid Medicine

Phyto Therapeutic Medicine for Inflammatory Conditions

Initial 2.2 Million Square Feet of Cultivation

Exclusive Clinically Validated Formulations

Innovation in Skin Care and Anti-Aging Systems

Relevium Executes LOI to Acquire Montreal Biopharma Contract Manufacturing Company

MONTREAL, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce it has executed a letter of intent to acquire a Montreal based biopharma contract...

Relevium Technologies Appoints Mark Billings as Chief Financial Officer

MONTREAL, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the appointment of Mark Billings, CFA as Chief Financial Officer for both Relevium and...

Relevium’s Subsidiary BGX E-Health Secures One Million Dollar Export Contract for the Middle East

MONTREAL, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that its wholly owned subsidiary, BGX E-Health LLC (“BGX”), has received a purchase order...

Relevium Technologies

Relevium is a publicly traded corporation strategically focused on the expansion and acquisition of entrepreneurial brands within the health and wellness sector. Our focus is on being a trusted source of high-quality nutraceutical and CBD products.